▶주메뉴 바로가기
▶본문 바로가기
Celltrion Group Chair and founder Seo Jung-jin downplayed concerns over potential fallout from recent US policy and tariff changes, saying the South Korean drugmaker remains on track to meet its annual revenue target of 5 trillion won ($3.58 billion) this year. “Concerns about the impact of recent US policy and tariff changes have been excessively amplified,” Seo said during an online briefing Thursday. “We see no effect on our business this year, and even next year, it could be an opportunity r
Korean biopharmaceutical company Celltrion has initiated direct sales operations in Spain, completing its transition to locally led sales across all major European markets, the company announced Wednesday. Following the conclusion of its partnership with former distributor Kern Pharma, Celltrion’s Spanish subsidiary will now manage local operations independently, directly distributing three oncology drugs: Truxima (rituximab), Herzuma (trastuzumab), and Vegzelma (bevacizumab). This strategic mov
Hugel Inc., a Korean medical aesthetics company, announced Tuesday that it hosted a launch event for its botulinum toxin product Botulax in Dubai, United Arab Emirates, marking its second official debut in the Middle East following Kuwait. Held aboard the Desert Rose Yacht on Friday, the event attracted approximately 180 local dermatologists and plastic surgeons, earning praise for its unique venue and premium presentation. Under the slogan “Your Next Move,” the launch signals Hugel’s strategic
South Korean biopharmaceutical firm Celltrion reported record first-quarter revenue and a sharp jump in profit, as robust global demand for its next-generation biosimilars improved margins. Operating profit soared a whopping 870 percent from a year earlier to 149.4 billion won ($107 million) in the January-March period, while consolidated revenue rose 14.2 percent to 841.9 billion won, the South Korean biopharmaceutical firm said Friday. The earnings boost was attributed to the end of amortizati
South Korea’s Cha Hospital and Cha University are exploring a research and academic partnership with Johns Hopkins Medicine International, following a high-level meeting held in Seoul last month. Johns Hopkins Medicine International is the global partnership arm of Johns Hopkins Medicine, which has been at the forefront of stem cell and organoid research, including breakthroughs in creating midbrain structures from stem cells. Key topics of discussion on April 24 included promoting joint researc
LG Chem, Korea’s leading chemical company, announced Thursday that it has begun the global expansion of its new diabetes combination drug Zemidapa, marking its first export milestone with a launch in Thailand. To kick off the launch, the company hosted the “Zemi-Connect Global” symposium in Bangkok, attended by over 120 endocrinologists from Korea, Thailand and the Philippines. The event was held alongside the International Diabetes Federation 2025 Congress, where LG Chem was a main sponsor. Zem
Matica Biotechnology Inc., a US subsidiary of South Korea-based biotechnology company CHA Biotech, has signed a strategic partnership agreement with the National Center for Therapeutics Manufacturing at Texas A&M University to accelerate the development of cell and gene therapies, or CGT. This collaboration merges Matica Bio’s manufacturing and regulatory expertise with NCTM’s early-stage research and development capabilities. The two organizations aim to provide an integrated service platform t
Miracell, a Korean biotech company, unveiled its plans to expand into the stem cell biohealth market in Dubai of the United Arab Emirates on Wednesday, as part of efforts to strengthen its presence in the Gulf Cooperation Council region. Dubai has become a key center for the medical and biohealth industries in the Middle East, driven by both rising demand for healthcare services and interest in technological innovation. Miracell aims to develop stem cell therapies for various diseases, providing
Samsung Biologics, the biotech arm of Samsung Group, has secured its second contract manufacturing deal this year, signing a major agreement worth 737.3 billion won ($513 million) with a US-based pharmaceutical company. In a regulatory filing Monday, the company said the new contract with the undisclosed partner will run through the end of 2031. The deal is equivalent to 16.2 percent of Samsung Biologics’ revenue in 2024. This latest win follows Samsung Biologics’ largest-ever contract manufactu
Cosmax Bio, a Korean original design manufacturer specializing in health functional foods, has obtained renewed halal certification for its Jecheon plant from the Korea Muslim Federation, the company said Monday. This move is part of the company’s broader strategy to expand into Indonesia, not only the world’s largest halal market but also one of the fastest-growing health markets. According to Euromonitor, Indonesia’s health functional food market is expected to reach approximately 3.65 trillio
Coupang, Wiley partner for speedy delivery of 50,000 titles across Korea
2025 Global Biz Forum highlights business opportunities in Vietnam
Nongshim's Shin Ramyun Toomba sells out in Japan
SK Group sets up cyber task force to bolster digital defenses
Czech-Korean nuclear deal under EU scrutiny
Saudi Aramco reaffirms commitment to Korea’s Shaheen project
May 16, 2025
May 16, 2025
May 14, 2025
May 13, 2025
May 11, 2025
May 9, 2025
May 8, 2025
May 7, 2025
April 30, 2025
April 28, 2025
April 28, 2025
